trial

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

NCTId NCT00477672
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 298 (actual)
Sponsored by ACADIA Pharmaceuticals Inc.
Primary completion 2009-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
298 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-06
Primary completion
2009-06
Eligibility
ALL · 40 Years

Interventions & indications

Drugs
Pimavanserin

Sponsors

ACADIA Pharmaceuticals Inc.Lead Sponsor

Sites

0 total

Linked catalysts

1
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Pa — primary completion2009-06

Facts & assertions

4 sourced
Enrollment
298
Phase
PHASE3
Primary Completion Date
2009-06
Status
COMPLETED
relationships
The graph out of here
drug
Pimavanserin
drug
lead_sponsor
ACADIA Pharmaceuticals Inc.
company
indication
Parkinson's Disease Psychosis
indication
Parkinson Disease
indication
Psychotic Disorders
indication